<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02580097</url>
  </required_header>
  <id_info>
    <org_study_id>MR-STARS-Radiology-ChinaPLAGH</org_study_id>
    <nct_id>NCT02580097</nct_id>
  </id_info>
  <brief_title>MR-based Stroke Mechanism and Future Risk Score</brief_title>
  <acronym>MR-STARS</acronym>
  <official_title>MR-based Stroke Mechanism and Future Risk Score</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore prediction model for outcome of patients with acute ischemic stroke using&#xD;
      multimodal Magnetic Resonance(MR) imaging was a multicenter prospective observational study&#xD;
      supported by National Natural Science Foundation of China. Imaging evaluation of hemodynamic&#xD;
      status and antegrade flow were assessed. Patients were followed up to record radiological and&#xD;
      clinical outcome. The study recruited patients from 11 centers located in 10 provinces or&#xD;
      province-level municipalities across the northeast to the southeast of China mainland.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients:&#xD;
&#xD;
      Patients with cerebral ischemia sympton of onset in 24 hours were included. Baseline&#xD;
      materials, NIH stroke scale score, modified Rankin Scale at admission, stroke causes, time&#xD;
      from sympton onset to enrollment were recorded.&#xD;
&#xD;
      Imaging scan were conducted at admission, within 7 days after admission.&#xD;
&#xD;
      Imaging protocols:&#xD;
&#xD;
      MRI scan protocols: T2 weighted image, T1 weighted image, Diffusion weighted image(DWI),&#xD;
      fluid-attenuated inversion recovery(FLAIR), Perfusion weighted image(PWI), arterial spin&#xD;
      labeling(ASL) , susceptibility-weighted imaging(SWI).&#xD;
&#xD;
      Contrast agent:&#xD;
&#xD;
      Omniscan 2ml/kg, Inject rate：3ml/s&#xD;
&#xD;
      Digital subtraction angiography(DSA) protocols:&#xD;
&#xD;
      Selective angiography and imaging phase from arterial phase to late venous phase.&#xD;
&#xD;
      Imaging evaluation:&#xD;
&#xD;
      Antegrade flow assessment from ASL Cerebral blood flow(CBF) map. Collateral flow assessment&#xD;
      from ASL CBF map, ASL subtraction CBF map, PWI postprocessing map, FLAIR hyperintensity&#xD;
      vascular sign.&#xD;
&#xD;
      Initial infarct volume measurement form DWI. Final infarct volume measurement from FLAIR.&#xD;
      DWI-ASPECTS. Stroke lesions pattern assessment identified on DWI. DSA antegrade and&#xD;
      collateral grade using modified Thrombolysis in Cerebral Infarction(TICI) scale and The&#xD;
      American Society of Interventional and Therapeutic Neuroradiology (ASITN) collateral grading&#xD;
      system.&#xD;
&#xD;
      Treatment:&#xD;
&#xD;
      Intravenous recombinant tissue plasminogen activator(rtPA), endovascular therapy and&#xD;
      conventional treatment including neuro protection, ante-platelet and statin.&#xD;
&#xD;
      Follow up:&#xD;
&#xD;
      within Seven days and a month after imaging follow up and clinical stroke event and modified&#xD;
      Rankin Scale(mRS) record in 1 year.&#xD;
&#xD;
      Note:&#xD;
&#xD;
      The original trial from 2015 to 2018 recruited patients with acute and subacute ischemic&#xD;
      stroke, and the trial plan was changed to recruit patients with acute cerebral ischemia&#xD;
      sympton of onset within 24 h.The study has been upgraded from a single-center study to a&#xD;
      multi-center study since 2018.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>modified Rankin Score</measure>
    <time_frame>Three months</time_frame>
    <description>Modified Rankin Score of patients with acute stroke after 3 months will be followed up for neurological outcome assessment. mRS &lt; 2 is defined as favorable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Final infarct volume</measure>
    <time_frame>Seven days to 1 month</time_frame>
    <description>Final infarct volume will be measured and infarct volume growth will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke event</measure>
    <time_frame>within 1 year</time_frame>
    <description>The patients will be monitored whether they recured ischemic stroke event including transient ischemic attack (TIA) or stroke confirmed by neurologist and diffusion-weighted image MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>within 1 year</time_frame>
    <description>The patient will be monitored for death by telephone follow-up for neurological outcome assessment</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">961</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Stroke</arm_group_label>
    <description>Ischemic stroke patients with sympton onset in 24 hours and no contradiction to MRI scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI perfusion imaging, including contrast bolus perfusion imaging and arterial spin labeling.</description>
    <arm_group_label>Stroke</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Ischemic stroke patients with sympton onset in 24 hours&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age≥18&#xD;
&#xD;
          -  Cerebral ischemic sympton with onset in 24 hours&#xD;
&#xD;
          -  pre mRS&lt;2&#xD;
&#xD;
          -  All MR examination performed according to study protocol&#xD;
&#xD;
          -  Signed informed consent obtained from the patient or patient's legally authorized&#xD;
             representative&#xD;
&#xD;
          -  Having complete medical history and clinical follow up&#xD;
&#xD;
          -  Imaging data can be processed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intracranial hemorrhage&#xD;
&#xD;
          -  Pregnancy and other contraindication to MRI scan&#xD;
&#xD;
          -  Informed consent not obtained&#xD;
&#xD;
          -  Pre-existing medical, neurological or psychiatric disease that would confound the&#xD;
             neurological, functional, or imaging evaluations&#xD;
&#xD;
          -  Known allergy to iodine previously refractory to pretreatment medications&#xD;
&#xD;
          -  Renal Failure (serum creatinine &gt; 2.0 or Glomerular Filtration Rate [GFR] &lt; 30)&#xD;
&#xD;
          -  History of sever kidney disease as an adult, including tumor or transplant surgery, or&#xD;
             family history of kidney failure&#xD;
&#xD;
          -  Severe cardiac insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Lou, M.D.,Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 16, 2015</study_first_submitted>
  <study_first_submitted_qc>October 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Xin Lou</investigator_full_name>
    <investigator_title>Deputy Chief of Radiology</investigator_title>
  </responsible_party>
  <keyword>Arterial Spin Labeling</keyword>
  <keyword>Ischemic stroke</keyword>
  <keyword>Collateral Circulation</keyword>
  <keyword>Perfusion imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

